Breaking News Instant updates and real-time market news.

WBA

Walgreens Boots Alliance

$76.95

1.12 (1.48%)

, AMZN

Amazon.com

$980.85

15.4 (1.60%)

10:51
10/06/17
10/06
10:51
10/06/17
10:51

Walgreens drops as analysts highlight guidance concerns, Amazon risk

Shares of Walgreens Boots Alliance (WBA) dropped in morning trading after an analyst downgraded the stock, saying he believes the company's guidance will fall short of consensus estimates. Separately, another analyst noted a threat to retail players like Walgreens from Amazon's (AMZN) potential entry into the drug distribution value chain. DOWNGRADE TO EQUAL WEIGHT: Ricky Goldwasser, an analyst at Morgan Stanley, cut his rating on Walgreens Boots Alliance to Equal Weight from Overweight, saying he believes the company's guidance will be below analysts' consensus estimates when it reports earnings on October 25 as its growth slows. Goldwasser, who also reduced his price target on shares to $85 from $95, told clients that the key driver of his lower estimates are the recent Medicare Part D preferred network exclusions, but also cited reimbursement cuts in the U.K. as well as reimbursement pressure in the U.S. He believes Walgreens will face a headwind to earnings per share of 11c-14c after being excluded from CVS Health's (CVS) Silverscript, Envision (EVHC), and Aetna's (AET) Medicare preferred networks, which could shift 4 million to 5 million scripts out of Walgreens' stores. In June, Walgreens reported quarterly earnings that beat analysts' estimates and raised the lower end of its fiscal 2017 EPS guidance to $4.98-$5.08, in line with analysts' estimates at the time of $5.00. CVS A BENEFICIARY: Separately, Goldwasser said CVS is viewed as beneficiary of preferred network dynamics next year, but he maintained his Equal Weight rating on the stock as he is below consensus for 2018 "as we see pricing dynamics offsetting some of the volume benefits." AMAZON THREAT: Amazon is said to be looking at entering the retail pharmacy industry, which may impact Pharmacy Benefit Managers, or PBMs. In a note to clients this morning, Leerink analyst Ana Gupte said she believes that Amazon "will almost certainly" enter the drug distribution value chain within two years, evolving into a more "disruptive" offering over time. She said Amazon's potential move is most threatening for retail players like Walgreens, as well as CVS and Wal-Mart (WMT), and provides both an opportunity and a threat for Express Scripts (ESRX). Gupte noted OptumRx (UNH) and Humana (HUM) would be "largely buffered" from the move. According to her conversations with specialists, Amazon is hiring relevant talent and is in active discussions with mid-market pharmacy benefit managers and possibly even with large players such as Prime Therapeutics. Additionally, she said she expects Aetna, Anthem (ANTM) and Cigna (CI) will likely contemplate Amazon's entry in their upcoming PBM contract decisions. PRICE ACTION: In morning trading, Walgreens Boots Alliance dropped 2% to $75.44. Shares are down over 8% year-to-date. OTHERS TO WATCH: Other retail pharmacies trading lower this morning include CVS Health and Rite Aid (RAD).

WBA

Walgreens Boots Alliance

$76.95

1.12 (1.48%)

AMZN

Amazon.com

$980.85

15.4 (1.60%)

CVS

CVS Health

$79.77

-1.13 (-1.40%)

EVHC

Envision Healthcare

$44.06

-0.51 (-1.14%)

AET

Aetna

$162.02

0.73 (0.45%)

WMT

Wal-Mart

$78.69

-0.72 (-0.91%)

ESRX

Express Scripts

$64.01

0.03 (0.05%)

UNH

UnitedHealth

$199.13

1.23 (0.62%)

HUM

Humana

$247.49

2.13 (0.87%)

ANTM

Anthem

$193.54

0.62 (0.32%)

CI

Cigna

$192.35

1.67 (0.88%)

RAD

Rite Aid

$2.04

-0.045 (-2.16%)

  • 08

    Oct

  • 10

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 25

    Oct

  • 25

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 12

    Dec

  • 20

    Feb

WBA Walgreens Boots Alliance
$76.95

1.12 (1.48%)

10/06/17
MSCO
10/06/17
DOWNGRADE
MSCO
Equal Weight
Walgreens Boots Alliance downgraded to Equal Weight at Morgan Stanley
10/06/17
10/06/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Spirit Airlines (SAVE) downgraded to Hold from Buy at Deutsche Bank with analyst Michael Linenberg saying the company's revenue outlook "may face greater downside risk" than peers given the competitive intensity of its markets. 2. Albemarle (ALB) downgraded to Neutral from Conviction Buy at Goldman Sachs with analyst Robert Koort saying the company over the past two years has transformed from a value-oriented chemical stock into a "thematic growth engine" as investors shifted their focus to the potential of an electric vehicle revolution. 3. Cree (CREE) downgraded to Underweight from Neutral at JPMorgan with analyst Paul Coster citing valuation. 4. Valero (VLO) downgraded to Neutral from Overweight at JPMorgan with Phil Gresh citing valuation following the recent rally. 5. Walgreens Boots Alliance (WBA) downgraded to Equal Weight at Morgan Stanley with analyst Ricky Goldwasser saying he expects the company's guidance to come in below consensus estimates when it is provided later this month. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/17
LEER
10/06/17
NO CHANGE
LEER
Leerink convinced Amazon entering drug distribution within two years
After calls with pharmacy benefit managers and retail pharmacy specialists, Leerink analyst Ana Gupte says she's convinced that Amazon.com (AMZN) "will almost certainly" enter the drug distribution value chain within two years, evolving into a more disruptive offering over time. Amazon's move is most threatening for retail pharmacies Walgreens Boots Alliance (WAB), CVS Health (CVS) and Wal-Mart (WMT), Gupte tells investors in a research note. The analyst calls Amazon both an opportunity and threat for Express Scripts (ESRX) and views UnitedHealth (UNH) and Humana (HUM) as "largely buffered." Gupte's conversations with specialists indicate Amazon is hiring relevant talent and is in active discussions with mid-market pharmacy benefit managers and possibly even with large players such as Prime Therapeutics. It is believed Amazon will start by capturing share in both the cash paying and third party mail order and possibly specialty pharmacy segments, Gupte notes. She expects Anthem (ANTM), Aetna (AET) and Cigna (CI) will likely to contemplate Amazon's entry in their upcoming PBM contract decisions.
10/06/17
10/06/17
DOWNGRADE
Target $85

Equal Weight
Walgreens downgraded to Equal Weight from Overweight at Morgan Stanley
As previously reported, Morgan Stanley analyst Ricky Goldwasser downgraded Walgreens Boots Alliance to Equal Weight from Overweight, as he expects the company's guidance to come in below consensus estimates when it is provided later this month. The key drivers he cites are recent Part D preferred network exclusions, as well as reimbursement cuts in the U.K. and reimbursement pressure in the U.S. Goldwasser, who notes the company's growth is slowing, cut his price target on Walgreens shares to $85 from $95.
AMZN Amazon.com
$980.85

15.4 (1.60%)

10/06/17
RILY
10/06/17
NO CHANGE
Target $250
RILY
Buy
Amazon's Seller Flex expansion unlikely to impact Stamps.com, says B. Riley
B. Riley analyst Kevin Liu believes Amazon.com's (AMZN) plans to expand its Seller Flex program more broadly in 2018 following a two-year pilot in India and testing in West Coast states, as reported yesterday by Bloomberg, is unlikely to impact Stamps.com (STMP). The Seller Flex program Seller Flex arranges for the pickup and delivery of merchandise from the seller's distribution facility, which could potentially impact volumes currently routed through the major domestic carriers, Liu tells investors in a research note. He believes FedEx (FDX) and UPS (UPS) have the most to lose given their exposure to large shippers. The analyst sees "little risk at present" to Stamps.com given that Seller Flex is targets merchants with a "far greater" assortment, order volumes, and logistical footprint than is typically targeted by the company's various brands. Liu reiterates a Buy rating on Stamps.com with a $250 price target.
10/06/17
BARD
10/06/17
NO CHANGE
BARD
Amazon implications negative for FedEx, UPS, says Baird
Baird analyst Benjamin Hartford noted reports Amazon (AMZN) is testing its own final mile delivery service in the U.S. and he believes it is a logical extension of its model as it builds network density. The analyst believes the implications for parcel providers FedEx (FDX) and UPS (UPS) are negative, as it could put pressure on delivery rates and volume may be diverted from both. Hartford continues to rate FedEx with an Outperform and $235 price target and UPS remains Neutral rated with a $125 price target.
10/06/17
ROTH
10/06/17
NO CHANGE
Target $21
ROTH
Neutral
New CEO to tackle distribution concerns at Vista Outdoor, says Roth Capital
Roth Capital analyst Dave King says that despite the announcement of a new CEO hire by Vista Outdoor (VSTO), he still remains concerned about the "sustainability of Vista's distribution competitive advantage" and soft performance from recent acquisitions. King writes that incoming CEO Chris Metz brings extensive experience in driving operational improvements, as the company continues to focus on expanding its e-commerce presence and possibly grow its business with Amazon (AMZN). The analyst is also positive on the opportunity to capture market share in the ammo downturn, maintaining a Neutral rating and his $21 price target on Vista.
CVS CVS Health
$79.77

-1.13 (-1.40%)

09/19/17
09/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Underperform at Jefferies. 2. DowDuPont (DWDP) initiated with a Buy at Argus. 3. Intuit (INTU) initiated with an Outperform at William Blair. 4. CVS Health (CVS) initiated with an Outperform at RBC Capital. 5. athenahealth (ATHN) initiated with a Sector Perform at RBC Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/19/17
RBCM
09/19/17
INITIATION
RBCM
Outperform
CVS Health initiated with an Outperform at RBC Capital
RBC Capital analyst George Hill started coverage of CVS with a $95 price target and an Outperform rating. He thinks that the company "could transform itself" by merging with a health insurance company, although he says that the chances of such a deal are "low." He estimates that such a deal could increase the company's EPS by over 10% and cause its multiple to rise by 200%-400%. Hill says that the stock's valuation is attractive even if the company does not make a deal.
09/14/17
LEER
09/14/17
NO CHANGE
LEER
Minimal hurricane exposure for pharma supply chain, says Leerink
Leerink analyst David Larsen sees less than 1% impact to revenues and earnings to companies in his coverage from Hurricane Harvey and Irma and believes any effects will be viewed as one-time in nature. The analyst notes that "the percentage of state impacted" and "days of impact" are particularly challenging variables in his model to estimate, but based on various assumptions he believes the hurricanes will prove to be a minor event for Express Scripts (ESRX), AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK). Nonetheless, Larsen says pharmacy retailers Walgreens Boots Alliance (WBA) and CVS Health (CVS) may face some store closures and possible damage costs.
EVHC Envision Healthcare
$44.06

-0.51 (-1.14%)

09/06/17
CANT
09/06/17
NO CHANGE
CANT
Overweight
Irma threat a risk for HCA, public hospital peers, says Cantor
Cantor Fitzgerald analyst Joseph France noted that HCA Holdings (HCA), Community Health (CYH), LifePoint (LPNT), Tenet (THC) and Envision Healthcare (EVHC) all have business in Florida and Texas and are all down today on the potential threat from Hurricane Irma and the impact from Hurricane Harvey last week. HCA reports nearly half of its beds are in Florida and Texas while Envision has said in the past that more than half of its anesthesia business and about half of its legacy ER business is in those two states, noted France, who adds that Community Health, LifePoint and Tenet are less exposed to those states. The analyst keeps an Overweight rating on HCA shares.
08/28/17
JEFF
08/28/17
NO CHANGE
JEFF
Buy
HCA has 11% of its beds in Harvey impacted areas, says Jefferies
Jefferies analyst Brian Tanquilut points out that HCA Holdings (HCA) has 11% of its beds in areas impacted by severe weather from Hurricane Harvey. The analyst expects the hurricane to cause a "notable disruption," specifically for hospitals, physician offices, surgery centers, and labs. Investors are likely to take a long-term view of Hurricane Harvey, however, as it is a one-time issue and thus excluded from operating and financial results, Tanquilut tells investors in a research note. He sees both Tenet (THC) and Community Health (CYH) being minimally impacted from the storm. Envision Healthcare's (EVHC) AmSurg segment has three ambulatory surgery centers in the impacted markets, while Surgery Partners (SGRY) has only one facility in Houston, the analyst adds.
09/19/17
JEFF
09/19/17
NO CHANGE
Target $71
JEFF
Buy
Envision Healthcare buyback a positive catalyst, says Jefferies
Jefferies analyst Brian Tanquilut views Envision Healthcare's introduction of a $250M share repurchase plan "as a notable positive" catalyst. The news underscores the board's confidence in the company's fundamental outlook and highlights the stock's discounted valuation, Tanquilut tells investors in a research note. The analyst is not surprised by the management changes and keeps a Buy rating on Envision with a $71 price target.
06/27/17
RBCM
06/27/17
NO CHANGE
RBCM
Envision Healthcare merger positive, says RBC Capital
After meeting with Envision's management, RBC Capital analyst Frank Morgan says he's "comfortable with the strategy behind" its merger with Amsurg Corp. The analyst thinks that the combined company "has the right model for the future of hospital-based medicine." He is upbeat on the company's longer term outlook and raised his price target o t he name to $77 from $72 while keeping an Outperform rating.
AET Aetna
$162.02

0.73 (0.45%)

09/12/17
ARGS
09/12/17
NO CHANGE
ARGS
Aetna price target raised to $185 from $165 at Argus
Argus analyst David Toung believes that Aetna reported "strong" Q2 results. The analyst remains upbeat on the company's 2H17 outlook and keeps a Buy rating on the shares.
10/02/17
BERN
10/02/17
NO CHANGE
BERN
Bernstein does not anticipate ACA fix/repeal before 2018 election
While noting the resignation of Health Secretary Tom Price, Bernstein analyst Lance Wilkes says he does not anticipate an Affordable Care act fix or ACA repeal before the 2018 election. The analyst expects tax reform will "suck the oxygen out of the room" until close to the election. A fix for 2019 is possible, but faces the headwind of the 2018 election campaign, he contends, adding that he believes CSR funding could be included in a trade for the upcoming budget and the Health Insurance Fee could be suspended as part of tax reform, but both are not highly likely at this point. Publicly traded companies in the space include Aetna (AET), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
07/14/17
PIPR
07/14/17
NO CHANGE
Target $18
PIPR
Overweight
Piper views updated Aetna policy as disappointing for Natera
Piper Jaffray analyst William Quirk views Aetna's (AET) updated non-invasive prenatal testing medical policy, where it decided to continue covering the test only in high risk, as "disappointing." Upside for Natera (NTRA) in the second half of 2017 now falls on Medicaid and microdeletion reimbursement progress, and less so commercial payers flipping to cover average risk, Quick tells investors in a research note. He keeps an Overweight rating on Natera shares with an $18 price target.
WMT Wal-Mart
$78.69

-0.72 (-0.91%)

09/06/17
FBCO
09/06/17
NO CHANGE
Target $43
FBCO
Underperform
Campbell Soup, Wal-Mart still negotiating, says Credit Suisse
Following up on Campbell Soup's (CPB) public disagreement in the soup category with Wal-Mart (WMT), Credit Suisse analyst Robert Moskow says the dispute specifically relates to Wal-Mart's demands for lower everyday price points on Campbell's condensed soup products. While this dispute does not appear to involve General Mills' (GIS) Progresso brand or the ready-to-serve category at this time, the analyst notes that Wal-Mart presumably could threaten to give more shelf space to General Mills or its Great Value brand at Campbell's expense. Campbell and Wal-Mart are still negotiating, Moskow points out, adding that it may be a good thing for the stock if Campbell can get Wal-Mart to agree to a compromise. The analyst reiterates an Underperform rating and $43 price target on Campbell's shares.
09/20/17
KEYB
09/20/17
NO CHANGE
KEYB
Toys R Us bankruptcy positive for Wal-Mart, Amazon, says KeyBanc
KeyBanc analyst Edward Yruma views the Toys R Us (TOY) bankruptcy as positive for both Wal-Mart (WMT) and Amazon (AMZN). The analyst believes that Wal-Mart's toy and baby business is over two times Toys R Us' domestic business and that its relative importance to the toy companies will only increase. Meanwhile, Yruma thinks Amazon's growth and convenience will drive continued share gains as well.
09/07/17
WELS
09/07/17
NO CHANGE
WELS
Market Perform
Perrigo signaled willingness to work with Amazon, says Wells Fargo
Wells Fargo analyst David Maris noted that while presenting yesterday at the firm's conference, Perrigo (PRGO) said it would welcome working with Amazon on store brands. Currently, online sales partnerships with e-commerce arms of existing retailers, such as Walmart (WMT) and Walgreens (WBA), account for 1% of Perrigo products, he added. Maris, who said the company made an "upbeat and confident presentation," keeps a Market Perform rating on Perrigo shares.
ESRX Express Scripts
$64.01

0.03 (0.05%)

07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
09/19/17
RBCM
09/19/17
INITIATION
RBCM
Sector Perform
Express Scripts initiated with a Sector Perform at RBC Capital
RBC Capital analyst George Hill started coverage of Express Scripts (ESRX) with a $68 price target and a Sector Perform rating. The analyst says that the company "faces an uncertain future" in the wake of the loss of its deal with Anthem ( ANTM), as he believes that it will have difficulty generating operating profit growth without Anthem.
UNH UnitedHealth
$199.13

1.23 (0.62%)

08/29/17
PIPR
08/29/17
NO CHANGE
Target $54.29
PIPR
Neutral
Piper says Advisory Board deal should be marginally accretive to UnitedHealth
Piper Jaffray analyst Sean Wieland said Advisory Board's (ABCO) deal to merge its healthcare business with United Healthcare's (UNH) OptumInsights should be marginally accretive to UnitedHealth and add to his confidence in his FY18 OptumInsights growth estimates. He keeps a Neutral rating on Advisory Board shares and raised his price target on the stock to $54.29 from $51 to reflect the combined estimated amount being paid to shareholders by Optum and Vista Equity, the buyers of Advisory's education business.
08/30/17
ADAM
08/30/17
DOWNGRADE
Target $54
ADAM
Hold
The Advisory Board downgraded to Hold from Buy at Canaccord
Canaccord analyst Richard Close downgraded The Advisory Board (ABCO) to Hold from Buy based on the announced transaction to split the company by selling the Healthcare business to UnitedHealth's (UNH) Optum unit and the Education Business to Vista Equity Partners. Close lowered his price target to $54.29 on Advisory Board shares.
HUM Humana
$247.49

2.13 (0.87%)

08/03/17
FBCO
08/03/17
NO CHANGE
Target $260
FBCO
Outperform
Humana price target raised to $260 from $250 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for Humana to $260 from $250 following quarterly results. The analyst reiterates an Outperform rating on the shares.
08/03/17
OPCO
08/03/17
NO CHANGE
Target $255
OPCO
Outperform
Humana price target raised to $255 from $236 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Humana to $255 from $236 following "strong results" that were driven by outperformance in Medicare Advantage, and after the company raised 2017 EPS guidance. The analyst reiterates an Outperform rating on the shares.
ANTM Anthem
$193.54

0.62 (0.32%)

07/12/17
FBCO
07/12/17
INITIATION
Target $195
FBCO
Neutral
Anthem initiated with a Neutral at Credit Suisse
Credit Suisse analyst Scott Fidel started Anthem with a Neutral rating and $195 price target. The company has produced slower earnings growth over the past decade relative to Managed Care peers and its returns on capital are also "sub-par relative to comps," the analyst contends. He believes Anthem is "entering a new chapter" following the failed Cigna (CI) acquisition and "uncertain future" of the Affordable Care Act's exchanges and Medicaid expansion.
CI Cigna
$192.35

1.67 (0.88%)

06/23/17
LEER
06/23/17
NO CHANGE
LEER
Outperform
Draft version of Senate healthcare bill better than expected, says Leerink
Leerink analyst Ana Gupte said she views the draft version of the Senate healthcare bill as better than expected, stating that stabilization of the Exchanges and risk stabilization is a direct positive for health insurers and indirect positive for facility operators. The Senate bill maintains the House bill's plan to repeal all "ObamaCare" industry fees and taxes, which is a positive for Managed Care and Medical Technology players, Gupte adds. She keeps Outperform ratings on Anthem (ANTM), UnitedHealth (UNH), Cigna (CI), Humana (HUM), WellCare (WCG), Molina Healthcare (MOH) and acute care hospital operators HCA Holdings (HCA), Tenet (THC) and LifePoint (LPNT).
RAD Rite Aid
$2.04

-0.045 (-2.16%)

09/19/17
RBCM
09/19/17
INITIATION
RBCM
Sector Perform
Rite Aid initiated with a Sector Perform at RBC Capital
RBC Capital analyst George Hill started coverage of Rite Aid with a $2.50 price target and a Sector Perform rating.
10/02/17
JEFF
10/02/17
NO CHANGE
Target $95
JEFF
Buy
Walgreens growth from Rite Aid stores not priced in, says Jefferies
Jefferies analyst Brian Tanquilut says he remains positive on Walgreens Boots Alliance (WBA) given his expectation for sustained double-digit earnings growth over the next few years. The acquisition of Rite Aid (RAD) stores will yield incremental earnings growth in the next few years that's not yet priced into the stock, Tanquilut tells investors in a research note. He believes that while Amazon (AMZN) risk to front-end pharmaceutical sales "is real," Walgreens has done better than peers in "weathering the storm." The analyst has a Buy rating on the shares with a $95 price target.
09/12/17
09/12/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DowDuPont (DWDP) initiated with an Outperform at Macquarie. 2. Bunge (BG) initiated with a Neutral at Baird. 3. Rite Aid (RAD) initiated with a Hold at Loop Capital. 4. Nike (NKE) was initiated with an Outperform at Bernstein, while Under Armour (UA) was initiated with an Underperform. 5. Houlihan Lokey (HLI) initiated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/17
LOOP
09/11/17
INITIATION
Target $2.5
LOOP
Hold
Rite Aid initiated with a Hold at Loop Capital
Loop Capital analyst Andrew Wolf started Rite Aid (RAD) with a Hold rating and $2.50 price target, stating that he views the company's re-worked store sale to Walgreens (WBA) as a "re-launch of Rite Aid's turnaround efforts" and believes it lacks intermediate term earnings visibility.

TODAY'S FREE FLY STORIES

YOGA

YogaWorks

$2.86

-0.04 (-1.38%)

07:07
10/19/17
10/19
07:07
10/19/17
07:07
Hot Stocks
YogaWorks acquires seven Houston studios »

YogaWorks announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QURE

uniQure

$9.47

-2.2 (-18.85%)

07:07
10/19/17
10/19
07:07
10/19/17
07:07
Hot Stocks
uniQure acquires patent family providing protection of FIX-Padua »

uniQure N.V. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEVA

CEVA

$45.15

-0.25 (-0.55%)

07:07
10/19/17
10/19
07:07
10/19/17
07:07
Hot Stocks
CEVA and Cyberon partner for voice activation solution for smartphones »

CEVA and Cyberon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

RCI

Rogers Communications

$53.75

-0.23 (-0.43%)

07:07
10/19/17
10/19
07:07
10/19/17
07:07
Hot Stocks
Breaking Hot Stocks news story on Rogers Communications »

Rogers Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

SBGI

Sinclair Broadcast

$30.35

0.3 (1.00%)

, TRCO

Tribune Media

07:06
10/19/17
10/19
07:06
10/19/17
07:06
Periodicals
FCC extends comment period for Sinclair-Tribune deal, Reuters reports »

The Federal…

SBGI

Sinclair Broadcast

$30.35

0.3 (1.00%)

TRCO

Tribune Media

DISH

Dish

$49.71

0.86 (1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

RCI

Rogers Communications

$53.75

-0.23 (-0.43%)

07:06
10/19/17
10/19
07:06
10/19/17
07:06
Earnings
Rogers Communications backs FY17 revenue growth view 3%-5% 

Consensus $11.34B.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

NAK

Northern Dynasty

$2.09

0.1 (5.03%)

07:06
10/19/17
10/19
07:06
10/19/17
07:06
Initiation
Northern Dynasty initiated  »

Northern Dynasty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESTE

Earthstone Energy

$10.54

-0.15 (-1.40%)

07:05
10/19/17
10/19
07:05
10/19/17
07:05
Syndicate
Earthstone Energy 4.5M share Spot Secondary priced at $9.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 16

    May

  • 19

    Oct

RCI

Rogers Communications

$53.75

-0.23 (-0.43%)

07:05
10/19/17
10/19
07:05
10/19/17
07:05
Hot Stocks
Rogers Communications raises FY17 adj operating profit growth view to 5%-6% »

With plans to invest the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

PM

Philip Morris

$112.51

-0.14 (-0.12%)

07:05
10/19/17
10/19
07:05
10/19/17
07:05
Hot Stocks
Philip Morris CEO says Q3 results 'very strong' »

"As expected, our…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

BX

Blackstone

$33.49

0.27 (0.81%)

07:05
10/19/17
10/19
07:05
10/19/17
07:05
Earnings
Blackstone reports Q3 ENI 69c, consensus 54c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 22

    Oct

  • 07

    Nov

ABCB

Ameris Bancorp

$49.45

0.3 (0.61%)

07:04
10/19/17
10/19
07:04
10/19/17
07:04
Earnings
Ameris Bancorp reports Q3 adjusted EPS 63c, consensus 65c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 15

    Nov

  • 28

    Nov

V

Visa

$107.80

0.26 (0.24%)

07:04
10/19/17
10/19
07:04
10/19/17
07:04
Hot Stocks
Visa announces security platform Visa ID Intelligence »

Visa announced Visa ID…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 29

    Nov

PM

Philip Morris

$112.51

-0.14 (-0.12%)

07:04
10/19/17
10/19
07:04
10/19/17
07:04
Earnings
Philip Morris revises FY17 reported EPS view to $4.75-$4.80, consensus $4.84 »

PMI revises its 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

SPX

S&P 500

07:04
10/19/17
10/19
07:04
10/19/17
07:04
Hot Stocks
Trump thinks Republicans have votes for budget approval »

President Trump just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCI

Rogers Communications

$53.75

-0.23 (-0.43%)

07:03
10/19/17
10/19
07:03
10/19/17
07:03
Earnings
Rogers Communications reports Q3 EPS C$1.01, consensus C$0.80 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

PM

Philip Morris

$112.51

-0.14 (-0.12%)

07:02
10/19/17
10/19
07:02
10/19/17
07:02
Earnings
Philip Morris reports Q3 adjusted EPS $1.27, consensus $1.38 »

Reports Q3 revenues,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

ERIC

Ericsson

$5.98

0.08 (1.36%)

07:02
10/19/17
10/19
07:02
10/19/17
07:02
Downgrade
Ericsson rating change  »

Ericsson downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$130.02

1.37 (1.06%)

07:01
10/19/17
10/19
07:01
10/19/17
07:01
Hot Stocks
Travelers reports Q3 combined ratio of 103.2% »

Including 10.7 points of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 13

    Nov

USO

United States Oil Fund

$10.48

-0.01 (-0.10%)

07:01
10/19/17
10/19
07:01
10/19/17
07:01
Technical Analysis
United States Oil Fund: Pivot points, pivot low edged »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOP

SPDR Oil Exploration and Production Fund

$33.35

-0.32 (-0.95%)

07:00
10/19/17
10/19
07:00
10/19/17
07:00
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$26.40

0.3 (1.15%)

06:59
10/19/17
10/19
06:59
10/19/17
06:59
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$130.02

1.37 (1.06%)

06:59
10/19/17
10/19
06:59
10/19/17
06:59
Hot Stocks
Breaking Hot Stocks news story on Travelers »

Travelers reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 13

    Nov

UGAZ

VelocityShares 3x Long Natural Gas ETN

$10.23

-0.17 (-1.63%)

06:58
10/19/17
10/19
06:58
10/19/17
06:58
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$130.02

1.37 (1.06%)

06:58
10/19/17
10/19
06:58
10/19/17
06:58
Hot Stocks
Travelers reports Q3 book value per share $86.73 »

Reports Q3 adjusted book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.